Opzelura was approved by the U.S. Food and Drug Administration (FDA) on September 20, 2021 [1]. It is available by prescription [2].
What is Opzelura used for?
Opzelura is a topical cream indicated for the short-term and non-continuous treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical therapies, or when those therapies are not advisable [3]. It is also indicated for the treatment of nonsegmental vitiligo in patients 12 years of age and older [3].
How does Opzelura work?
Opzelura is a Janus kinase (JAK) inhibitor. By inhibiting JAK enzymes, it helps to reduce inflammation and modulate the immune response in the skin [3].
When can I expect Opzelura to be available?
Opzelura became available after its FDA approval in September 2021 [1].
Who makes Opzelura?
Incyte Corporation developed Opzelura [3].
How does Opzelura compare to other atopic dermatitis treatments?
Opzelura offers a topical treatment option for atopic dermatitis that targets inflammation differently than traditional topical corticosteroids or calcineurin inhibitors [3]. Its mechanism as a JAK inhibitor represents a newer class of therapy for managing the condition.
Are there any patent concerns for Opzelura?
Information regarding specific patent expirations and potential patent challenges for Opzelura can be found on resources like DrugPatentWatch.com [4]. Patents play a crucial role in determining the period of market exclusivity for a drug.
What are the potential side effects of Opzelura?
Common side effects reported with Opzelura include nasopharyngitis, application site pruritus, and headache [3]. Patients should discuss potential risks and side effects with their healthcare provider [3].
What are the considerations for using Opzelura for vitiligo?
For nonsegmental vitiligo, Opzelura is used to help re-pigment the skin [3]. Treatment response can vary among individuals.
Are there any restrictions on Opzelura use?
Opzelura is for topical use only and is not recommended for use in patients who are immunocompromised [3]. It is also not recommended for use in combination with other topical JAK inhibitors, other biologic drugs, or full-JAK inhibitory medicines [3].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[2] https://www.opzelura.com/
[3] https://www.opzelura.com/atopic-dermatitis/how-it-works
[4] https://www.drugpatentwatch.com/